Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Prilenia, Ferrer entered collaboration agreement for commercialization and co-development of pridopidine in Europe and other ...

Houston mortgage duo Cissy and Christopher Larkin are channeling a four-year ALS battle into a widespread fundraiser.

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.

Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415mn deal, expanding its neuroscience pipeline with a novel, ...

ALS patient Bradford Smith became the third patient to test Neuralink — and the first one to do so who had lost the ability ...

Alchemab Therapeutics, a next-gen biopharmaceutical company, has entered into a licensing agreement with Eli Lilly and ...

Amyotrophic lateral sclerosis (ALS)—known as Lou Gehrig's Disease, based on the iconic 1930s New York Yankee baseball ...

The global amyotrophic lateral sclerosis market is on an upward trajectory, demonstrating significant potential for growth and innovation. According to the latest insights from Future Market Insights ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...